预约演示

更新于：2025-02-06

Dextromethorphan Hydrobromide Hydrate

氢溴酸右美沙芬

更新于：2025-02-06

概要

基本信息

简介右美沙芬（DXM）是可待因的合成类似物，但与可待因不同，它不是一种麻醉药物，也没有相同的滥用或成瘾潜力。DXM是N-甲基-D-天门冬氨酸（NMDA）受体拮抗剂，NMDA受体参与疼痛知觉、情绪调节、学习和记忆的调节。DXM是σ-1受体激动剂，σ-1受体参与许多不同的功能，包括疼痛感知、情绪调节和神经保护。右美沙芬通常用作咳嗽抑制剂，并已被研究其在多种疾病中的潜在治疗作用，包括神经病性疼痛、抑郁症和成瘾。1954年，DXM在美国海军和中央情报局资助的研究非成瘾性可待因替代品的检测中被发现。它于1958年被FDA批准为非处方咳嗽抑制剂。

药物类型

小分子化药

别名

Dextromethorphan Hydrobromide、Dextromethorphan Hydrobromide Cranules、Dextromethorphan Hydrobromide Granules

+ [29]

靶点

NMDA receptor x σ1 receptor

作用机制

NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)、σ1 receptor激动剂(σ-阿片受体激动剂)

治疗领域

呼吸系统疾病

在研适应症

干咳咳嗽

非在研适应症-

原研机构

Shionogi Pharma Co., Ltd.

在研机构

Shionogi Pharma Co., Ltd.

广州白云山光华制药股份有限公司Tsuruhara Pharmaceutical Co. Ltd.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1958-01-01),

咳嗽

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C18H28BrNO2

InChIKeySTTADZBLEUMJRG-IKNOHUQMSA-N

CAS号6700-34-1

关联

158

项与氢溴酸右美沙芬相关的临床试验

NCT06383338

/ Not yet recruiting临床1期

A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.

PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.

开始日期2025-03-01

申办/合作机构

Murdoch Childrens Research Institute

NCT06716645

/ Recruiting临床4期

A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.

开始日期2024-12-04

申办/合作机构

Haleon Plc

NCT06632990

/ Active, not recruiting临床1期

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together. Most drugs are broken down and cleared in the body via cytochrome P450 enzymes in the liver. The metabolism and clearance of certain drugs can be affected by other drugs when dosed together. To evaluate the impact of BMS-984923 on the clearance of other medications, we will investigate three known pathways which may be impacted by BMS-984923.
In this study participants will take one dose of the three known medications, midazolam, caffeine and dextromethorphan together. These drugs are known to be cleared by different cytochrome P450 enzymes. Blood will be collected to evaluate the exposure and clearance of these medications and their primary metabolites. Study participants will then be administered BMS-984923 for 18-days. On the 18th Day of BMS-984923 dosing, participants will again be co-administering midazolam, caffeine and dextromethorphan. Blood will be collected again, and the concentration of each drug will be measured. We will learn in this study if BMS-984923 changes the exposure and metabolism of the known drugs. These results will inform how BMS-984923 can be administered to patients who take multiple medications.

开始日期2024-11-21

申办/合作机构

Allyx Therapeutics, Inc.初创企业

[+1]

100 项与氢溴酸右美沙芬相关的临床结果

登录后查看更多信息

100 项与氢溴酸右美沙芬相关的转化医学

登录后查看更多信息

100 项与氢溴酸右美沙芬相关的专利（医药）

登录后查看更多信息

2,796

项与氢溴酸右美沙芬相关的文献（医药）

2025-03-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Ultrasensitive analysis of the commonly abused CNS antitussive, dextromethorphan in biological fluids and dosage forms using a novel micellar-sensitized spectrofluorimetric approach: Compliance with greenness and blueness metrics

Article

作者: Saleh, Safaa F ; El-Maghrabey, Mahmoud ; Ibrahim, Angum M M ; Al-Khateeb, Lateefa A ; Alsehli, Bandar R ; Alshehri, Sultan ; Alsaggaf, Wejdan T ; Magdy, Galal ; El Hamd, Mohamed A ; Radwan, Aya Saad ; Mahdi, Wael A

The current study introduces the first micellar-enhanced spectrofluorimetric approach for the estimation of the commonly abused CNS antitussive, dextromethorphan (DXM) in its syrup and biological fluids. A micellar solution of sodium dodecyl sulfate (SDS) containing DXM showed high native fluorescence emission at 305 nm following excitation at 224 nm. Using SDS as a micellar system resulted in about a 2.5-fold increase in the drug's fluorescence intensity and quantum yield as well as the sensitivity of the approach. A thorough investigation was conducted into the experimental factors affecting the studied drug's spectrofluorimetric behavior. Additionally, the quantum yield of DXM was calculated, and it was found to reach up to 22 %. A calibration plot with a straight line was produced across the concentration range of 10.0-200.0 ng/mL. The suggested approach demonstrated excellent sensitivity down to the nanogram level, with 1.80 ng/mL for the detection limit and 5.47 ng/mL for the quantification limit. The drug under study was successfully analyzed in syrup using the designed approach, which yielded low %RSD values (≤0.882) and high %recoveries (99.20-101.00). The efficacy of the suggested fluorimetric technique in detecting DXM in human plasma and urine samples has been demonstrated with excellent recovery (98.12-101.35) and %RSD (≤1.39) values owing to its high sensitivity and selectivity. As DXM is one of the most commonly abused CNS antitussives, the capacity of the proposed method for its analysis in biological fluids can provide further insights for monitoring its potential abuse. The excellent greenness and eco-friendliness of the method were confirmed using GAPI and AGREE metrics, while the BAGI tool assessed its economy, practicality, and applicability. The method was fully validated according to ICH Q2 (R2) guidelines.

2025-03-01·JOURNAL OF HAZARDOUS MATERIALS

Antitussive drug dextromethorphan induces developmental impairment in zebrafish

Article

作者: Lu, Zhi-Jie ; Li, Si-Ying ; Zhang, Jin-Ge ; Hu, Li-Xin ; Huang, Chu-Shu ; Huang, Zheng ; Ma, Dong-Dong ; Ying, Guang-Guo ; Shi, Wen-Jun ; Long, Xiao-Bing ; Liu, Xin

Dextromethorphan (DXM) is a common ingredient in cough and cold remedies. Despite its widespread presence in aquatic environments, the impact of DXM on fish remains largely unknown. This study evaluated the developmental impairment of zebrafish embryos exposed to DXM from 2 hours post-fertilization (hpf) to 14 days post-fertilization (dpf) at five different exposure concentrations: 0.06, 0.61, 8.12, 76.3, and 827 μg/L. Results indicated a concentration-dependent increase in bioconcentration of DXM at 7 dpf and 14 dpf. The LC₅₀ at 14 dpf was 93.3 μg/L, demonstrating DXM has a high toxicity to zebrafish larvae. Additionally, DXM reduced body length and heart rate, and elevated malformation in a dose-dependent manner in larvae at 72 hpf, 7 dpf and 14 dpf. Biochemical analysis (DNA conformations and 8-hydroxy-2deoxyguanosine level) and transcriptomic analysis (DNA damage and cell cycle) indicated that DXM triggered DNA damage in larvae. Concurrently, DXM triggered DNA damage response (e.g., cell cycle arrest, DNA repair failure, and cell apoptosis) in larvae at 7 dpf and 14 dpf. These results help explain DXM caused severe developmental impairment via DNA damage-related pathways in zebrafish larvae, highlighting the importance of focusing on ecological and public health risks of DXM in natural environment.

2025-02-01·CNS DRUGS

Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease

Review

作者: Mazzacane, Federico ; Gatti, Alberto ; Perini, Giulia ; Imbimbo, Camillo ; Leone, Silvia ; De Franco, Valentino ; Cotta Ramusino, Matteo ; Costa, Alfredo

Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes. While nonpharmacological treatments may alleviate mild behavioral symptoms, more severe syndromes often require pharmacological intervention. Brexpiprazole is the only medication approved for agitation in AD, although its limited clinical efficacy has raised criticism. No drugs have been approved for treating psychosis in AD, highlighting the critical need for new, effective, and safe treatments. Recent studies have elucidated part of the neurobiological basis of NPSs in the AD brain, offering insights for testing repurposed and novel drugs. We conducted a comprehensive nonsystematic literature review, aiming to provide a critical overview of both current treatments and emerging pharmacological interventions under clinical development for treating psychosis and agitation in AD. Additionally, we present strategies to optimize the clinical development of new drug candidates. We identify three promising compounds that are currently in phase 3 trials: xanomeline-trospium for AD psychosis, and dextromethorphan-bupropion and dexmedetomidine for agitation in AD. We propose that biomarkers linked to the neuropsychiatric traits of AD patients should be identified in dedicated studies and then included in phase 2 dose-range-finding studies with novel compounds to establish biological engagement. Furthermore, phase 3 placebo-controlled studies should be carried out in AD biomarker-confirmed subjects with narrower cognitive impairment ranges and precise NPS severity at screening. Alternative study designs, such as sequential phase approaches, may also be adopted.

200

项与氢溴酸右美沙芬相关的新闻（医药）

2025-01-25

·生物世界

Cell：竺淑佳/李扬团队首次在原子分辨率上看清调控学习和记忆的“分子开关”NMDA受体的精细结构

编辑丨王多鱼排版丨水成文学习和记忆是人类认知和感知世界的高级脑功能，突触可塑性的改变被认为是学习和记忆的物质基础。N-甲基-ᴅ-天冬氨酸（N-methyl-ᴅ-aspartate，简称为NMDA）受体是一类存在于突触上的离子型谷氨酸门控通道家族，广泛参与神经发育、突触可塑性、学习记忆、认知及情绪等高级脑功能调控，被视为学习和记忆的关键“分子开关”。 NMDA 受体在负责学习和记忆相关高级认知功能的脑区（如大脑皮层和海马）发挥着至关重要的作用，受体通道对钙离子具备高通透性，根据突触活动的强弱调控突触连接的强度，并参与下游信号介导基因的表达和新突触的形成。近年来的临床医学研究揭示 NMDA 受体功能障碍直接与一系列神经及精神疾病密切相关，包括 NMDA 受体突变相关的罕见病、癫痫、精神分裂症和自身免疫性脑炎等。因此，NMDA 受体一直是脑疾病领域药物设计最热门的靶点，已有靶向 NMDA 受体的分子（如氯胺酮、美金刚、右美沙芬）用于临床治疗抑郁症和阿尔茨海默症。在哺乳动物中，NMDA 受体由 7 个不同基因编码形成 7 个不同亚基。有功能的 NMDA 受体通常由两个必需的 GluN1 亚基和两个可变的 GluN2/3（N2A-N2D，N3A-N3B）亚基组装形成二异或三异四聚体（图1）。过去十年内，利用体外重组表达系统，NMDA 受体亚型的结构与功能已被大量解析，其中竺淑佳团队在该领域也取得了系列进展（Cell 2016；Cell Rep 2018；Nature 2021；Neuron 2021；Nat Struct & Mol Biol 2023、2024）。然而，大脑中内源 NMDA 受体的亚基表达和受体组装受到严格的大脑发育时空变化调控。脑内调控学习与记忆的是哪些内源 NMDA 受体，它们在大脑中的占比是怎样的，它们的组装形式和已知的异源重组受体是否存在差异，系列问题极大限制了对突触分子功能的理解。图1. NMDA受体亚基时空表达和四聚体组装的多样性。功能性NMDA受体由两个必需的GluN1亚基和两个可变的GluN2或GluN3亚基组装形成四聚体。在不同的发育阶段，脑内关键NMDA受体不同亚型的分布及功能存在多样性。 2025年1月23日，中国科学院脑科学与智能技术卓越中心（神经科学研究所）竺淑佳团队和中国科学院上海药物研究所李扬团队合作，在国际顶尖学术期刊 Cell 上发表了题为：Assembly and architecture of endogenous NMDA receptors in adult cerebral cortex and hippocampus（成年哺乳动物大脑皮层和海马内源 NMDA 受体的组装和结构）的研究论文。研究团队通过提取大鼠大脑皮层和海马中的内源 NMDA 受体并解析出 3 种主要亚型及比例，揭示内源 NMDA 受体的原子分辨率三维结构，突破了 NMDA 受体的分子结构与功能研究局限于异源重组表达系统的瓶颈。该成果为开发靶向 NMDA 受体治疗神经或精神类疾病的新型药物提供了重要的理论基础。为了从脑组织中分离出内源 NMDA 受体，竺淑佳团队通过多年的技术积累，定制了靶向各个 NMDA 受体亚基的构象特异性单克隆抗体。团队通过异源重组表达的不同 NMDA 亚型蛋白逐一免疫小鼠，通过杂交瘤技术及活细胞染色筛选出了靶向 NMDA 受体各亚基的选择性单抗（图2）。借助这些实验室自制的超高亲和力抗体工具（亲和力在纳摩尔数量级），研究团队成功从成年大鼠的大脑皮层和海马中富集和分离出了丰度极低的内源 NMDA 受体。图2. 靶向NMDA受体亚基的高亲和力单抗的开发和内源NMDA受体的富集纯化策略。杂交瘤技术及活细胞荧光成像方法制备及鉴定结合不同NMDA受体亚型的单克隆抗体。利用纳摩尔级别的GluN1单抗纯化出皮层海马中内源NMDA受体，并加入构象特异性和亚基选择性的GluN2抗体进行标记及分析。通过冷冻电镜（cryo-EM）技术，研究团队从皮层和海马中的内源 NMDA 受体解析出了 3 种主要的受体亚型：GluN1-N2A-N2B 三异四聚体，GluN1-N2B 和 GluN1-N2A 二异四聚体，分别占据 45%、35% 和 20% 的比例（图3）。该研究表明 GluN1-N2A-N2B 三异四聚体是内源丰度最高的亚型，强调了 GluN2A 和 GluN2B 亚基在生理状态同一受体中的功能整合。更新了领域内三十年来认为发育关键期（developmental switch）是从 GluN1-2B 转变为 GluN1-2A 的观点，应修正为从出生时 GluN1-2B 转变为成年的 GluN1-2A-2B、GluN1-2B 和 GluN1-2A 三种亚型共存的结论。图3. 皮层和海马内源NMDA受体的主要亚型和不同亚基在单细胞转录组水平上的分布。研究团队进一步通过结构对比，发现了 GluN2B 亚基在 GluN1-N2A-N2B 三异四聚体和 GluN1-N2B 二异四聚体中的构象区别，揭示了同一亚基在不同受体中存在构象差异，将决定不同亚型的生物物理学、药理学和通道开放属性（图4）。不同内源 NMDA 受体间的构象差异，为理解内源 NMDA 受体的功能多样性，以及不同受体的药理差异提供了分子基础。该发现为设计具有亚基特异性且具有亚型偏好性的化合物提供了可能，有助于提高 NMDA 受体药物的靶向性。图4. 内源NMDA受体亚型间的构象及药理学特性差异该研究范式突破了几十年来 NMDA 受体的分子结构局限于体外异源重组表达系统的瓶颈，首次在原子分辨率上“看到”调控哺乳动物学习和记忆的“分子开关”的精细结构，揭示了内源 NMDA 受体的组装和组成，不仅加深了神经科学领域对 NMDA 受体介导的突触可塑性、学习和记忆等生理功能的理解，更为后续研究基于 NMDA 受体功能障碍相关脑疾病的机制和治疗，揭示靶向 NMDA 受体临床药物的在体作用机制奠定了重要的理论依据。中国科学院脑智卓越中心和上海药物研究所联合培养博士研究生张明为论文第一作者，中国科学院脑智卓越中心竺淑佳研究员和中国科学院上海药物研究所李扬研究员为论文共同通讯作者。竺淑佳团队的冯娟副研究员协助数据分析，谢春和宋楠制备并鉴定了亚基特异性抗体；北京蛋白质组中心的王建研究员和金超智完成了质谱鉴定；大连化物所赵群和张丽华研究员开展了交联质谱分析；脑智卓越中心孙怡迪研究员和王波爽开展了转录组数据分析。论文链接： https://www-cell-com.libproxy1.nus.edu.sg/cell/fulltext/S0092-8674(25)00033-9 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

2025-01-24

·学术经纬

揭秘学习记忆的“分子开关”！今日《细胞》解析哺乳动物大脑内源NMDA受体结构

▎药明康德内容团队编辑学习和记忆是人类认知和感知世界的高级脑功能，突触可塑性的改变被认为是学习和记忆的物质基础。N-甲基-ᴅ-天冬氨酸（简称 NMDA）受体是一类存在于突触上的离子型谷氨酸门控通道家族，广泛参与神经发育、突触可塑性、学习记忆、认知及情绪等高级脑功能调控，被视为学习和记忆的关键“分子开关”。 NMDA受体在负责学习和记忆相关高级认知功能的脑区（如大脑皮层和海马）发挥着至关重要的作用。近年来的临床医学研究揭示，NMDA受体功能障碍与一系列神经及精神疾病密切相关，因此NMDA受体一直是脑疾病领域药物设计最热门的靶点，目前已有靶向NMDA受体的分子（如氯胺酮、美金刚、右美沙芬）用于临床治疗抑郁症和阿尔茨海默病。在哺乳动物中，NMDA受体由7个不同基因编码形成7个不同亚基。有功能的NMDA受体通常由两个必需的GluN1亚基和两个可变的GluN2/3（N2A-N2D，N3A-N3B）亚基组装形成二异或三异四聚体。已有的研究已经大量解析了NMDA受体亚型的结构与功能，但这些研究依赖于体外重组表达系统，而关于大脑中内源NMDA受体仍有一系列未解之谜：脑内调控学习与记忆的是哪些内源NMDA受体？它们在大脑中的占比是怎样的？它们的组装形式和已知的异源重组受体是否存在差异？这些问题极大限制了对突触分子功能的理解。 ▲NMDA受体亚基时空表达和四聚体组装的多样性。功能性NMDA受体由两个必需的GluN1亚基和两个可变的GluN2或GluN3亚基组装形成四聚体。在不同的发育阶段，脑内关键NMDA受体不同亚型的分布及功能存在多样性。（图片来源：研究团队提供）今天，中国科学院脑科学与智能技术卓越中心（神经科学研究所）竺淑佳研究组在《细胞》（Cell）期刊发表论文，从大鼠大脑皮层和海马中提取出内源NMDA受体并解析出3种主要亚型及比例，揭示内源NDMA受体的原子分辨率三维结构，突破了NMDA受体的分子结构与功能研究局限于异源重组表达系统的瓶颈。该成果为开发靶向NMDA受体治疗神经或精神类疾病的新型药物提供了重要的理论基础。该研究的第一个挑战是从脑组织中分离出内源NMDA受体。竺淑佳团队通过多年的技术积累，定制了靶向各个NMDA受体亚基的构象特异性单克隆抗体。团队通过异源重组表达的不同NMDA亚型蛋白逐一免疫小鼠，通过杂交瘤技术及活细胞染色筛选出了靶向NMDA受体各亚基的选择性单抗。借助这些实验室自制的超高亲和力抗体工具，研究团队成功从成年大鼠的大脑皮层和海马中富集和分离出了丰度极低的内源NMDA受体。 ▲靶向NMDA受体亚基的高亲和力单抗的开发和内源NMDA受体的富集纯化策略。（图片来源：研究团队提供）通过冷冻电镜（cryo-EM）技术，研究团队从皮层和海马中的内源NMDA受体解析出了3种主要的受体亚型：GluN1-N2A-N2B三异四聚体，GluN1-N2B和GluN1-N2A二异四聚体，三者分别占据45%，35%和20%的比例。由此，研究表明GluN1-N2A-N2B三异四聚体是内源丰度最高的亚型，强调了GluN2A和GluN2B亚基在生理状态同一受体中的功能整合。 ▲皮层和海马内源NMDA受体的主要亚型和不同亚基在单细胞转录组水平上的分布。（图片来源：研究团队提供）此外，研究还修正了对内源性NMDA受体亚基转变模式的认知。内源性NMDA受体的亚基组成会响应不同发育阶段的突触信号而发生变化，传统观点认为在发育关键期，GluN1-2B会转变为GluN1-2A。而根据这项研究，出生时的GluN1-2B转变为成年的GluN1-2A-2B、GluN1-2B和GluN1-2A三种亚型共存的模式。接下来，研究团队进一步通过结构对比发现了GluN2B亚基在GluN1-N2A-N2B三异四聚体和GluN1-N2B二异四聚体中的构象区别，揭示了同一亚基在不同受体中存在构象差异，将决定不同亚型的生物物理学、药理学和通道开放属性。不同内源NMDA受体间的构象差异，为理解内源NMDA受体的功能多样性，以及不同受体的药理差异提供了分子基础。该发现为设计具有亚基特异性且具有亚型偏好性的化合物提供了可能，有助于提高NMDA受体药物的靶向性。 ▲内源NMDA受体亚型间的构象及药理学特性差异。（图片来源：研究团队提供）综上，该研究范式突破了几十年来NMDA受体的分子结构局限于体外异源重组表达系统的瓶颈，首次在原子分辨率上“看到”调控哺乳动物学习和记忆的“分子开关”的精细结构，揭示了内源NMDA受体的组装和组成，不仅加深了神经科学领域对NMDA受体介导的突触可塑性、学习和记忆等生理功能的理解，更为后续研究基于NMDA受体功能障碍相关脑疾病的机制和治疗，揭示靶向NMDA受体临床药物的在体作用机制奠定了重要的理论依据。该论文第一作者张明是中国科学院脑智卓越中心和上海药物研究所李扬课题组联合培养的博士研究生。竺淑佳团队的冯娟副研究员协助数据分析，谢春和宋楠制备并鉴定了亚基特异性抗体；北京蛋白质组中心的王建研究员和金超智完成了质谱鉴定；大连化物所赵群和张丽华研究员开展了交联质谱分析；脑智卓越中心孙怡迪研究员和王波爽开展了转录组数据分析。该工作获得了国家科技创新2030计划、国家自然科学基金、中国科学院青年交叉团队和上海分院青年攀登计划、上海市科技重大专项等项目资助。封面图来源：123RF 参考资料： [1] Zhang et al., Assembly and architecture of endogenous NMDA receptors in adult cerebral cortex and hippocampus. Cell (2025). DOI: 10.1016/j.cell.2025.01.004 本文来自药明康德内容微信团队，欢迎转发到朋友圈，谢绝转载到其他平台。如有开设白名单需求，请在“学术经纬”公众号主页回复“转载”获取转载须知。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。更多推荐点个“在看”再走吧~

临床研究

2025-01-23

·Endpoints

Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent said it will manufacture Galapagos’ clinical-stage CAR T therapy, dubbed GLPG5101, for upcoming clinical trials. Manufacturing will be done at Catalent’s site in Princeton, NJ, according to the Tuesday release. Kindeva Drug Delivery’s subsidiary Meridian Medical Technologies has secured a $129 million contract to supply DuoDote, an antidote for a chemical nerve agent, to the US Strategic National Stockpile, the company said Jan. 16. Dr. Reddy’s reported 83.6 billion rupees ($967 million) in revenues for the three months ending December 2024, which is 4% up from the 7.1 billion rupees ($82 million) it reported for the same period last year, the company said Thursday. The US contributes to 40% of its quarterly revenue. Solarbiotech, GPC Bio and Eleszto Genetika are consolidating into one company to provide services in biomanufacturing, the companies said Wednesday. The consolidation brings together over 100 engineers, scientists and executives. Afrigen Biologics has received $6.2 million from the Coalition for Epidemic Preparedness Innovations to develop an mRNA vaccine for Rift Valley fever, the company said Monday. Rift Valley fever is spread by mosquitoes, with outbreaks mainly reported in sub-Saharan Africa. Eli Lilly and Merck are collaborating with Purdue University to launch a new manufacturing consortium called the Young Institute Pharmaceutical Manufacturing Consortium, according to a Friday release. It will use technology like AI to improve domestic manufacturing in the US. AGC Biologics will manufacture and supply lentiviral vectors to Adaptimmune for the company to use in its T-cell therapy letetresgene autoleucel, as announced Jan. 16. Genethon and Eukarÿs have partnered to develop a technology to cut the cost of making gene therapies, according to a Thursday release. Eukarÿs will provide its engineered enzyme, dubbed C3P3, and Genethon will design and manufacture AAV vectors and provide its biomanufacturing facilities. In the UK, Bells Healthcare is recalling 17 batches of its cough syrup medicines containing the API dextromethorphan hydrobromide, according to a Tuesday announcement. Foreign material was found in some bottles and was categorized as a Class 2 recall.

疫苗财报信使RNA免疫疗法临床结果

100 项与氢溴酸右美沙芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氢溴酸右美沙芬	R05DA09	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
干咳	中国	广州白云山光华制药股份有限公司	1990-01-01
咳嗽	美国	Shionogi Pharma Co., Ltd.	1958-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03076021 (CTgov)	临床4期	与 CYP2D6 相关的药物代谢不良	33	isotretinoin (Pre-isotretinoin)	願鏇窪餘餘鑰艱艱遞衊(齋窪製範製鹹鹹鹹窪夢) = 蓋鬱齋構觸夢蓋齋淵製膚壓築襯顧淵鏇憲餘鏇 (廠餘鑰糧積淵糧夢廠積, 憲艱選鬱壓遞鑰艱網鹽 ~ 簾鏇製選廠窪壓積壓餘) 更多	-	2025-01-28
				Isotretinoin (With Isotretinoin)	願鏇窪餘餘鑰艱艱遞衊(齋窪製範製鹹鹹鹹窪夢) = 襯簾願憲蓋簾願構壓廠膚壓築襯顧淵鏇憲餘鏇 (廠餘鑰糧積淵糧夢廠積, 觸蓋顧夢築糧獵簾廠網 ~ 觸獵鹽醖醖鹽蓋願願範) 更多
NCT04392011 (CTgov)	早期临床1期	-	15	midazolam HCl+dextromethorphan HBr (Drug Cocktail)	鬱製艱顧憲範簾鬱願衊(醖鏇糧獵觸築積廠壓淵) = 網築廠夢繭醖構襯餘鹽範憲衊網製選願築窪鹽 (鏇願範衊壓顧選顧齋壓, 鏇餘夢齋願淵構窪積襯 ~ 衊觸網鹽壓範觸鑰觸夢) 更多	-	2023-06-08
				Kratom (Kratom + Drug Cocktail)	鬱製艱顧憲範簾鬱願衊(醖鏇糧獵觸築積廠壓淵) = 夢壓觸遞夢艱齋選鬱淵範憲衊網製選願築窪鹽 (鏇願範衊壓顧選顧齋壓, 獵觸窪顧鹹餘鹽積壓糧 ~ 觸鬱顧醖齋壓築觸獵顧) 更多
NCT03883581 (CTgov)	临床1/2期	肌萎缩侧索硬化	28	dextromethorphan HBr+quinidine sulfate	觸範積鹹鹽餘鏇選齋夢(鏇簾鑰鹽齋鏇醖鹹簾鏇) = 繭繭範鹹襯鹹製積鏇觸積壓衊鏇遞糧觸窪襯鏇 (廠鬱壓顧網願膚構獵簾, 廠衊製簾繭獵齋觸鬱繭 ~ 網淵積範蓋築餘壓鏇膚) 更多	-	2023-03-08
CTRI/2020/06/026115 (Pubmed \| Respirology)	N/A	咳嗽	112	Dextromethorphan syrup 30 ml (90 mg)	鹽顧艱壓鹽簾艱鹹夢繭(壓築獵願餘糧齋選壓憲) = 艱夢鏇顧鏇願齋製艱鑰構築範簾製顧範襯醖廠 (齋製構壓鹽淵壓膚鹽窪 ) 更多	-	2023-01-10
				Placebo	鹽顧艱壓鹽簾艱鹹夢繭(壓築獵願餘糧齋選壓憲) = 醖簾鑰廠顧齋夢窪窪築構築範簾製顧範襯醖廠 (齋製構壓鹽淵壓膚鹽窪 ) 更多
NCT03538054 (CTgov)	临床2期	纤维肌痛	27	Dextromethorphan (Dextromethorphan)	窪憲衊獵鬱觸齋糧願獵(鹹顧網蓋觸廠積鏇壓廠) = 製蓋廠膚廠醖願蓋鏇夢淵製選製鑰鏇鏇製醖廠 (獵繭觸廠願網壓醖遞艱, 願顧鑰鹽糧襯顧壓製選 ~ 齋鹹窪衊鏇鑰構衊窪遞) 更多	-	2022-08-26
				Placebo (Placebo)	窪憲衊獵鬱觸齋糧願獵(鹹顧網蓋觸廠積鏇壓廠) = 鏇憲壓糧淵夢餘積網壓淵製選製鑰鏇鏇製醖廠 (獵繭觸廠願網壓醖遞艱, 製鑰壓簾鏇網鹽構鹹築 ~ 廠積築鬱壓顧構網構積) 更多
NCT02651116 (CHPA DXM, CTgov)	临床4期	咳嗽	131	Cough recording device+Dextromethorphan Hydrobromide (Dextromethorphan Hydrobromide)	遞製膚鬱艱蓋遞艱築餘(糧衊獵顧淵鹽淵簾衊遞) = 淵網觸齋網壓襯鹹廠膚艱願糧餘鬱製鏇顧構壓 (範積選積鹹夢網願窪範, 衊顧製窪遞顧蓋遞簾憲 ~ 製淵衊淵鹹醖顧製廠願) 更多	-	2021-04-28
				Cough recording device (Placebo)	遞製膚鬱艱蓋遞艱築餘(糧衊獵顧淵鹽淵簾衊遞) = 構構鹹選窪構夢夢壓鬱艱願糧餘鬱製鏇顧構壓 (範積選積鹹夢網願窪範, 簾壓壓夢遞範觸鹹築繭 ~ 鏇遞夢膚願襯鹽壓遞願) 更多
NCT03714919 (CTgov)	临床2期	腺样体肥大	10	Dexmedetomidine+Acetaminophen+Dextromethorphan+Ketamine	鏇蓋網蓋窪衊餘製製網(醖壓憲製鬱壓選淵鬱製) = 蓋餘積鹹餘襯齋襯構願壓艱壓齋衊艱膚鏇簾鹽 (遞積簾膚築鬱積獵憲遞, 願範膚觸艱網壓齋積繭 ~ 獵鬱壓鹹構顧壓積網積) 更多	-	2021-02-05
NCT03480009 (DexMab, CTgov)	临床3期	习惯性流产 \| 疼痛	156	Dextromethorphan Hydrobromide+Oxycodone (Dextromethorphan, Opted for Narcotic Prescription)	壓鹽鬱齋簾簾鑰製艱觸(選觸餘選獵選鹹築窪餘) = 餘網廠簾觸遞鹽簾鬱夢壓糧願鹹積簾鬱網鹹顧 (壓繭糧襯壓淵憲繭積鬱, 積獵製觸餘製觸築鑰衊 ~ 製蓋選簾構鹽艱餘觸簾) 更多	-	2020-08-06
				Avicel PH101 (Microcrystalline Cellulose NF) for Compounding+Oxycodone (Placebo, Opted for Narcotic Prescription)	壓鹽鬱齋簾簾鑰製艱觸(選觸餘選獵選鹹築窪餘) = 膚夢獵壓鹹選鬱齋簾製壓糧願鹹積簾鬱網鹹顧 (壓繭糧襯壓淵憲繭積鬱, 壓簾艱積餘遞糧繭壓製 ~ 築壓鏇淵壓鹽壓願壓淵) 更多
NCT01441102 (Pubmed \| Transl Vis Sci Technol)	临床1/2期	糖尿病性黄斑水肿	5	Dextromethorphan 60 mg	簾鹹願製淵醖憲網壓夢(鏇鏇觸艱繭鏇襯鬱鑰積) = 膚膚顧餘窪醖衊廠觸鏇壓齋淵衊膚選襯積壓範 (憲觸鬱鏇艱餘鏇築鑰顧 ) 更多	-	2018-11-01
NCT01361217 (FLUOXETINE, CTgov)	N/A	药物相互作用	10	Lovastatin+Omeprazole+midazolam+caffeine+Fluoxetine+dextromethorphan	鹽憲糧廠構觸願顧範鏇(憲廠範構壓糧鹽範壓築) = 選範鏇鬱餘壓願繭繭築廠壓積選築繭顧膚蓋鑰 (鏇遞艱蓋鑰膚醖積選築, 築鹹衊窪艱淵膚淵艱網 ~ 範製壓鬱壓鏇糧簾糧簾) 更多	-	2018-06-29